Handheld AI-guided heart ultrasound to find heart valve disease earlier in older adults
Tests AI-guided handheld heart ultrasound to detect heart disease earlier in older adults.
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the 2 sites
- Trial code
- Registry title
- Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)
- Status
- Not yet recruiting
- People taking part
- 1,088 people, planned
- Starts
- 15 Dec 2026
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.)
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 to 85 at a regular clinic visit, and for the primary care and geriatrics providers who see them. It tests an AI-guided handheld heart ultrasound for finding heart valve disease earlier.
- Age
- Patients: 65 to 85 years, inclusive.
- Sex
- All sexes can join.
- Disease stage
- Patients must not already have known heart valve disease or weak heart function on an earlier echocardiogram. They must not have self-reported structural heart disease.
- Earlier treatment
- Patients must not have had surgery or a catheter procedure for aortic or mitral valve disease.
Main reasons for not taking part
- Echocardiogram done within the past 5 years
- At least moderate aortic or mitral valve disease, or ejection fraction 50% or less, on a prior echocardiogram
- Self-reported structural heart disease
- Significant frailty or illness limiting life expectancy to 1 year or less
- Unable to give informed consent
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Provider (cluster) participants:
- Physician or advanced practice provider (physician assistant or nurse practitioner) practicing in primary care or geriatrics at a participating institution who independently assesses patients
- Patient panel comprising >50% adults aged 65 years or older
- Sees patients in ambulatory clinic at least 1 day per week on average
- Agrees to participate, to undergo randomization, and to permit inclusion of all eligible patients from the panel
- Provides written informed consent; Patient participants:
- Adults aged 65 to 85 years, inclusive
- Attending a scheduled outpatient visit at a participating geriatrics or primary care clinic
- Willing and able to provide written informed consent and, if the AI-POCUS screen is positive, to return for a confirmatory echocardiogram
Who cannot take part
- History of surgical or transcatheter intervention for aortic or mitral valve disease
- Self-reported structural heart disease
- At least moderate aortic or mitral valve disease, or left ventricular ejection fraction 50% or less, documented on any prior echocardiogram
- Provider (cluster) participants:
- Serving in a locum tenens or other temporary capacity
- Unwilling or unable to nominate an AI-POCUS champion from the clinic; Patient participants:
- Echocardiogram performed within the past 5 years
- Significant frailty burden or comorbidities limiting life expectancy to; 1 year or less
- Unable to provide informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 85 years old?
Where in United States
- Parkland HealthDallas, United StatesContact: Dharam J Kumbhani, MD, SM, MRCP, FACC, FAHA, FSCANot yet recruiting
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Dharam J Kumbhani, MD, SM, MRCP, FACC, FAHA, FSCANot yet recruiting
About the trial
What the trial wants to find out
Heart valve disease and weakened heart muscle (left ventricular systolic dysfunction) are common in older adults and often go undetected until serious complications such as heart failure develop. Detection currently depends on a clinician hearing a murmur and then ordering an echocardiogram, which is easily missed or delayed.
Read full original descriptionShow less
This study tests whether a brief, artificial intelligence (AI)-guided handheld heart ultrasound - point-of-care ultrasound, or POCUS - performed by trained clinic staff during a routine visit identifies these conditions earlier than usual care.
Primary care and geriatrics providers, rather than individual patients, are assigned by chance to one of two groups. Patients seen by providers in the AI-ultrasound group are offered a POCUS scan and a one-time blood test at their regular visit, and are referred for a confirmatory echocardiogram if the scan is abnormal. Patients seen by providers in the usual care group receive standard clinic care. Researchers will compare how often previously undiagnosed structural heart disease is newly identified in each group.
The 2 groups in the trial
- AI-POCUS ScreeningTreatment being tested
Trained clinic staff perform AI-guided point-of-care ultrasound using the Kosmos Torso-One device on eligible patients during routine primary care or geriatrics visits. Patients with ≥ moderate valvular heart disease or EF ≤50% are referred for confirmatory echocardiography within 90 days.
Treatment: Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.)
- Usual CareNo study treatment, for comparison
Eligible patients receive standard provider-driven care. Echocardiography referral occurs per routine clinical indications such as auscultated murmur or patient-reported symptoms.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)
- Plain-language title
- Handheld AI-guided heart ultrasound to find heart valve disease earlier in older adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07756398, who can take part
- Record updated
- 3 November 2026